Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial

Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

Envafolimab Submits New Drug Application for Advanced Biliary Tract Cancer, Accepted for Review by NMPA

Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer

TASTE-2 Study Published in The BMJ: Combination of Cerebral Cytoprotection and Thrombectomy Significantly Reduces Post-Stroke Disability

China Daily | Simcere eyes growing pharmaceutical niche

Envafolimab Granted FDA Orphan Drug Designation for Gastric and GEJ Cancer

SIM0610, Simcere Zaiming's a Bispecific Antibody-Drug Conjugate Approved for Clinical Trials

Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

Simcere Zaiming Announces Inclusion of Enzeshu^® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List